



Obese living kidney donors: a comparison of hand-assisted retroperitoneoscopic versus laparoscopic living donor nephrectomy

Kosei Takagi^{1,2} · Hendrikus J. A. N. Kimenai¹ · Jan N. M. IJzermans¹ · Robert C. Minnee¹

Received: 22 May 2019 / Accepted: 12 November 2019
© The Author(s) 2019

Abstract

Background The aim of this study was to examine the difference in outcome between hand-assisted retroperitoneoscopic and laparoscopic living donor nephrectomy in obese donors, and the impact of donor body mass index on outcome.

Methods Out of 1108 living donors who underwent hand-assisted retroperitoneoscopic or laparoscopic donor nephrectomy between 2010 and 2018, 205 were identified having body mass index ≥ 30 . These donors were included in this retrospective study, analyzing postoperative outcomes and remnant renal function.

Results Out of 205 donors, 137 (66.8%) underwent hand-assisted retroperitoneoscopic donor nephrectomy and 68 donors (33.2%) underwent laparoscopic donor nephrectomy. Postoperative outcome did not show any significant differences between the hand-assisted retroperitoneoscopic donor nephrectomy group and the laparoscopic donor nephrectomy group in terms of major complications (2.2% vs. 1.5%, $P=0.72$), postoperative pain scale (4 vs. 4, $P=0.67$), and the length of stay (3 days vs. 3 days, $P=0.075$). The results of kidney function in donors after nephrectomy demonstrated no significant differences between the groups. Additional analysis of 29 donors with body mass index ≥ 35 (14.1%) as compared with 176 donors with body mass index 30–35 (85.9%) revealed no significant differences between groups in postoperative outcomes as well as kidney function after donation.

Conclusion Our results show that laparoscopic living donor nephrectomy for obese donors is safe and feasible with good postoperative outcomes. There were no significant differences regarding postoperative outcome between hand-assisted retroperitoneoscopic and laparoscopic donor nephrectomy. Furthermore, the outcome in donors with body mass index ≥ 35 was comparable to donors with body mass index 30–35.

Keywords Kidney transplantation · Living donors · Nephrectomy · Laparoscopy · Hand-assisted laparoscopy · Obesity

Kidney transplantation is the most effective option in treating end-stage renal disease. Due to a persistent shortage of deceased donor organs, living donor kidney transplantation is considered as an excellent alternative to expand the kidney donor pool. Careful selection criteria for living donors are warranted because donor nephrectomy can cause complications, including short-term and long-term, in healthy

individuals. The body mass index (BMI) is one of the simple parameters used for donor selection. In most transplant centers, a BMI ≥ 35 is considered as a relative contraindication to be a donor [1–4]; however clear cut-off values of BMI are still under debate and further investigations are needed to clarify the significance of donor BMI on outcome not only in donors but also in recipients.

A previous meta-analysis reported that donors with BMI ≥ 30 had significantly longer operative time, higher conversion risk, and increased serum creatinine levels after laparoscopic donor nephrectomy, even though other short-term outcome such as postoperative complications, length of stay (LOS) did not show significant differences [5]. In contrast, the Organ Procurement and Transplantation Network registry data have shown good outcomes for obese donors (BMI ≥ 30) and their recipients [6]. However, the question whether laparoscopic living donor nephrectomy is safe and

✉ Kosei Takagi
kotakagi15@gmail.com

¹ Division of HPB & Transplant Surgery, Department of Surgery, Erasmus MC, University Medical Centre Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands

² Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan

feasible in obese donors, and whether there are any differences regarding short-term outcome between hand-assisted retroperitoneoscopic (HARP) and pure laparoscopic (LDN) living donor nephrectomy in obese donors, is unknown.

The aim of this study was to compare the outcome between HARP and LDN in donors with BMI ≥ 30 . Furthermore, we evaluated the impact of donor BMI on outcome after living donor nephrectomy.

Materials and methods

We retrospectively reviewed the kidney transplant database including 1108 consecutive living donors who underwent a donor nephrectomy at the Erasmus MC, University Medical Centre Rotterdam, The Netherlands, between January 2010 and December 2018. Among 1108 living donors, 205 donors with BMI ≥ 30 were extracted. This study was approved by the Ethics Committee of the Erasmus MC, and was conducted in accordance with the tenets of the Declaration of Helsinki.

Clinical data

For all enrolled donors, the following demographic and clinical data were collected: gender, age, height, weight, BMI, American Society of Anesthesiologists (ASA) physical status, history of hypertension, and relationship between donors and recipients. BMI was categorized into two groups: BMI 30–35 and BMI ≥ 35 . Regarding the operative outcome, the type of donor nephrectomy (HARP vs. LDN), the side of the donor nephrectomy (right vs. left kidney), conversion rate to open donor nephrectomy, operative time and blood loss were evaluated. Data on major postoperative complications, mortality, maximum pain scale after surgery until discharge, and the postoperative LOS were recorded as postoperative outcomes. The postoperative major complications were defined as Clavien-Dindo classification grade 3 or higher [7]. Pain scale was evaluated by the Numeric Pain Rating Scale in which a patient selected a whole number (0–10 integers): 0, no pain; 1–3, mild pain; 4–6, moderate pain; 7–10, severe pain [8]. Serum creatinine level (mg/dL) and the estimated glomerular filtration rate (eGFR, mL/min/1.73 m²) before donor nephrectomy and after 1 month, 3 month, and 1 year were analyzed.

Surgical technique

The details of surgical techniques employed were previously described [9, 10]. The selection for LDN or HARP was based on the surgeon preference. Both procedures were performed with the donor placed in right- or left-decubitus position. In LDN, the first trocar was introduced

under direct vision, the abdomen was insufflated with carbon dioxide to 14 cmH₂O pressure and a 30° video endoscope and 3 or 4 additional trocars were introduced. The colon was mobilized and displaced medially, and opening of the renal capsule and division of the perirenal fat was facilitated using an ultrasonic device (Harmonic, Ethicon, Cincinnati, USA). After identification and dissection of the ureter, the renal artery, and the renal vein, a Pfannenstiel incision was made. An endobag (Endocatch, US surgical, Norwalk, USA) was introduced into the abdomen. The ureter was clipped distally and divided. The renal artery and vein were divided using an endoscopic stapler (EndoGia, US Surgical, Norwalk, USA). The kidney was placed in the endobag and extracted through the Pfannenstiel incision.

In HARP, we started with a 7–10 cm Pfannenstiel incision. After blunt dissection to create a retroperitoneal space, a Gelport (Applied Medical, Rancho Santa Margarita, California, USA) was inserted. Blunt introduction of the first trocar between the iliac crest and the handport was guided by the operating surgeon's hand inside the abdomen through the Gelport. Carbon dioxide was insufflated retroperitoneally to 14 cm H₂O pressure. Two other 10–12 mm trocars, just outside the midline inferior to the costal margin and in the flank respectively, were inserted to create a triangular shape. For dissection, the aforementioned Harmonic device was used. Dissection of the kidney and dissection and cutting of the renal vessels and ureter were similar to transperitoneal donor nephrectomy but with hand assistance and from a slightly different angle. The kidney was extracted manually and flushed on the back table.

Statistical analysis

First, donor characteristics and outcome were compared between HARP and LDN groups. Second, the outcome between donors with BMI 30–35 and with BMI ≥ 35 was analyzed. Finally, the outcome of donors with BMI ≥ 30 was compared to those with BMI < 30 using a propensity score matching (PSM). The PSM was conducted using a logistic regression model including preoperative variables with *P* value < 0.20 (6 variables in total), as previously reported [11]. Propensity scores were matched with one-to-one ratio using a caliper width 0.20 of the standard deviation. Data were presented as medians and the interquartile range (IQR) for continuous variables. Categorical data were presented as proportions. Differences between groups were assessed using the Mann–Whitney U-test for continuous variables, and Fisher's exact test or Chi square test for categorical variables. JMP version 11 software (SAS Institute, Cary, NC) was used for all statistical analyses. A *P* value < 0.05 was considered statistically significant.




Fig. 1 Annual volume of HARP and LDN in obese donors between 2010 and 2018 at Erasmus MC. HARP, hand-assisted retroperitoneoscopic living donor nephrectomy; LDN, laparoscopic living donor nephrectomy

Results

Study cohort

The annual volumes of living donor nephrectomy in donors with BMI ≥ 30 between 2010 and 2018 at the Erasmus MC are shown in Fig. 1. The demographic characteristics of the 205 donors are shown in Table 1. Hypertension was found in 43 donors (21.0%). Regarding the relationship between donors and recipients, 101 (49.2%) were related, 67 (32.7%) were unrelated, 26 (12.7%) were cross over, and 11 (5.4%) were non-directed. Regarding operative outcome, 153 (74.6%) were left and 52 (25.4%) were right donor nephrectomy. Conversion rate to open donor nephrectomy was 0%. The median operative time was 161 min (IQR, 128–193 min) and the median blood loss was 168 mL (IQR, 50–330 mL). The incidence of postoperative major complications was 2.0%. There was no reoperation or mortality after surgery. The maximum pain scale after surgery was 4 (IQR, 2–5). The median LOS was 3 days (IQR, 3–4 days).

Table 1 Characteristics between HARP and LDN in donors with BMI ≥ 30

	Total	HARP	LDN	<i>P</i> value
No of donors	205	137	68	
Gender (M/F)	79/126	58/79	21/47	0.11
Age (years)	50.5 (41–60.3)	51.8 (42.5–60.7)	48.3 (37.5–58.6)	0.12
Height (cm)	169 (163.5–177)	170 (165–178)	167.5 (162.3–174.8)	0.03
Weight (kg)	93 (85–102.5)	95 (87–104.3)	90 (83–97.8)	0.002
BMI (kg/m ²)	32.4 (31.1–33.9)	32.6 (31.2–34.1)	31.8 (30.8–33.4)	0.034
ASA (1/2/3)	96/108/1	63/73/1	33/35/0	0.64
Hypertension	43 (21.0)	31	12	0.41
Relationship				
Related	101 (49.2)	66	35	0.047
Unrelated	67 (32.7)	50	17	
Cross over	26 (12.7)	12	14	
Non-directed	11 (5.4)	9	2	
Operative				
Right/left kidney	52/153	29/108	23/45	0.053
Conversion to open	0 (0)	0 (0)	0 (0)	–
Time (min)	161 (128–193)	165 (133–198)	155 (116–190)	0.10
Blood loss (mL)	168 (50–330)	200 (100–400)	67.5 (20–200)	< 0.001
Postoperative				
Major complications (CDc ≥ 3)	4 (2.0)	3 (2.2)	1 (1.5)	0.72
Reoperation	0 (0)	0 (0)	0 (0)	–
Mortality	0 (0)	0 (0)	0 (0)	–
Pain scale (max)	4 (2–5)	4 (2–5)	4 (2.3–5)	0.67
LOS (days)	3 (3–4)	3 (3–4)	3 (2–3)	0.075

Data were presented as numbers (percentages) or median (interquartile range)

HARP hand-assisted retroperitoneoscopic living donor nephrectomy, LDN laparoscopic living donor nephrectomy, BMI body mass index, ASA American Society of Anesthesiologists physical status, CDc Clavien–Dindo classification, LOS length of stay

Comparison between hand-assisted retroperitoneoscopic versus pure laparoscopic donor nephrectomy in donors with BMI ≥ 30

Perioperative outcomes are also summarized in Table 1. Out of 205 donors, 137 (66.8%) underwent HARP and 68 (33.2%) underwent LDN. BMI was significantly higher in the HARP group than that in the LDN group (32.6 kg/m² vs. 31.8 kg/m², $P=0.034$). Left donor nephrectomy was more common in the HARP group compared to the LDN group (78.8% vs. 66.2%, $P=0.053$). The operative time was not significantly different (165 min vs. 155 min, $P=0.10$); however, blood loss was significantly higher in the HARP group (200 mL vs. 67.5 mL, $P<0.001$). Postoperative outcome did not show any significant differences between the HARP group and the LDN group in terms of major complications (2.2% vs. 1.5%, $P=0.72$), pain scale (4 vs. 4, $P=0.67$), and the LOS (3 days vs. 3 days, $P=0.075$).

The results of kidney function after nephrectomy are shown in Table 2. Serum creatinine level and the eGFR before nephrectomy and after 1 month, 3 month, and 1 year demonstrated no significant differences between the groups.

Comparison between donors with BMI 30–35 versus with BMI ≥ 35

The results of comparison between donors with BMI 30–35 and with BMI ≥ 35 are shown in Table 3. 176 donors (85.9%) were identified having BMI 30–35 and 29 (14.2%) having BMI ≥ 35 . No significant differences between the groups were found in terms of demographic characteristics and operative factors. Regarding postoperative outcome, there were no significant differences between the two groups in the incidence of major complications (1.7% vs. 3.5%, $P=0.56$)

and the LOS (3 days vs. 3 days, $P=0.68$). The results of kidney function showed no significant differences between the groups. At 1 year after nephrectomy, rise in creatinine and decline in eGFR were similar between donor BMI categories.

Comparison between donors with BMI < 30 versus with BMI ≥ 30 using the propensity score matching

Donor characteristics before and after PSM are demonstrated in Table 4. Donors with BMI ≥ 30 were younger and had higher ASA and more hypertension than donors with BMI < 30. In addition, LDN was much common in donors with BMI < 30 than those with BMI ≥ 30 (77.9% vs 33.2%, $P<0.001$). After PSM, both groups were well adjusted for matched variables. The receiver- operating characteristic curve area under curve was 0.778. Postoperative outcomes and kidney function were not significantly different between the groups.

Discussion

The present study shows the clinical outcome after laparoscopic living donor nephrectomy in a single-center series of 205 donors with BMI ≥ 30 at the Erasmus MC. The results suggest that laparoscopic living donor nephrectomy for donors with BMI ≥ 30 is safe and feasible with good postoperative outcomes including no conversion rate, low major complication risk, and short LOS. In addition, we found no significant differences between HARP and LDN in terms of operative outcome, postoperative outcome and postoperative kidney function except for blood loss.

Table 2 Perioperative kidney function between HARP and LDN in donors with BMI ≥ 30

	Total ($n=205$)	HARP ($n=137$)	LDN ($n=68$)	P value
Creatinine (mg/dL)				
Pre	73 (65.5–83)	73 (65.5–82.5)	73 (64.5–83)	0.84
1 month	111 (96–128)	112 (96–129)	108 (96.3–124)	0.61
3 month	109 (95–123)	111 (96–123.5)	105 (92–123.8)	0.56
1 year	106 (93–123)	106 (94–123)	105 (93–123)	0.62
Delta (1 year—pre)	34 (27–42.8)	34 (27–45)	33 (25.5–41)	0.24
eGFR (mL/min/1.73 m ²)				
Pre	85 (73.5–90)	84 (73–90)	86 (74–90)	0.24
1 month	52 (45–59)	51 (44–58)	53 (46–60)	0.39
3 month	53 (46–61)	52 (46–60)	55.5 (46–63)	0.35
1 year	54 (48–61)	54 (48–61)	55 (48.5–60)	0.79
Delta (1 year—pre)	–27 (–33 to –23)	–27 (–33 to –23)	–27 (–33 to –22)	0.90

Data were presented as median (interquartile range)

HARP hand-assisted retroperitoneoscopic living donor nephrectomy, LDN laparoscopic living donor nephrectomy, eGFR estimated glomerular filtration rate

Table 3 Characteristics between donors with BMI 30–35 versus with BMI ≥ 35

	BMI 30–35	BMI ≥ 35	P value
No of donors	176	29	
Gender (M/F)	71/105	8/21	0.18
Age (years)	50.5 (41.1–61.3)	49.9 (42.3–55.6)	0.66
ASA (1/2/3)	85/91/0	11/17/1	0.09
Hypertension	34	9	0.17
Operative			
HARP/LDN	116/60	21/8	0.48
Right/left kidney	46/130	6/23	0.52
Conversion to open	0 (0)	0 (0)	–
Time (min)	161 (127–192)	162 (134–209)	0.62
Blood loss (mL)	165 (50–300)	200 (18.5–392)	0.95
Postoperative			
Major complications (CDc ≥ 3)	3 (1.7)	1 (3.5)	0.56
LOS (days)	3 (3–4)	3 (2.5–4)	0.68
Kidney function			
Creatinine (mg/dL)			
Pre	73.5 (66–82.8)	68 (61–83.5)	0.20
1 month	111 (97–128)	104 (88.5–123.3)	0.16
3 month	110 (96–124)	102 (92–122)	0.16
1 year	107 (95–124)	101 (91.5–122)	0.41
Delta (1 year—pre)	34 (27–43)	35 (24–43)	0.60
eGFR (mL/min/1.73 m ²)			
Pre	85 (73–90)	86 (76–90)	0.82
1 month	51 (44.3–58.8)	52.5 (48.3–63.3)	0.32
3 month	53 (46–60)	56 (47–61)	0.51
1 year	54 (48–61)	54 (47.5–62)	0.72
Delta (1 year—pre)	–27 (–33 to –23)	–27 (–31 to –20.5)	0.58

Data were presented as numbers (percentages) or median (interquartile range)

BMI body mass index, *ASA* American Society of Anesthesiologists physical status, *HARP* hand-assisted retroperitoneoscopic living donor nephrectomy, *LDN* laparoscopic living donor nephrectomy, *CDc* Clavien–Dindo classification, *LOS* length of stay, *eGFR* estimated glomerular filtration rate

Furthermore, no impact of donor BMI on perioperative outcome and kidney function was found between donors with BMI 30–35 and with BMI ≥ 35 as well as between donors with BMI < 30 and with BMI ≥ 30 .

Regarding postoperative outcomes in donors with BMI ≥ 30 , all procedures were done laparoscopically with no conversion to open donor nephrectomy and no reoperation after surgery. The outcome was better when compared with previous studies that reported the conversion rate to open procedure with 1.6–2.7% and reoperation with 0.2–0.4% in donors with BMI ≥ 30 [5, 6, 12]. Our institute is one of the largest centers in living kidney donation and transplantation in Western Europe, therefore the beneficial effect of hospital volumes might result in better outcome. Actually several studies have reported that outcomes at higher volume centers are better following laparoscopic donor nephrectomy and kidney transplantation [13–15].

No previous studies have investigated the outcome between HARP and LDN in donors with BMI ≥ 30 so far. Our results demonstrated that operative and postoperative outcomes as well as postoperative kidney function did not show any differences except for intraoperative blood loss. Therefore we believe LDN would be possible even in donors with BMI ≥ 30 . Actually 57% of procedures were done by LDN in 2017 and 2018. In contrast, HARP was often conducted at the left kidney (78.8%), although not statistically significant. HARP is considered more challenging at the right side, due to interference of the liver. Furthermore, the use of HARP or LDN did not have any effect on postoperative pain.

With respect to comparison between donors with BMI 30–35 and with BMI ≥ 35 , donors with BMI ≥ 35 had comparable operative and postoperative outcomes to donors with BMI 30–35. Furthermore, donors with BMI ≥ 30 had

Table 4 Characteristics of donors with BMI < 30 and BMI ≥ 30: overall and propensity score matching cohort

Variables	Before PSM (<i>n</i> = 1108)			After PSM (<i>n</i> = 402)		
	BMI < 30	BMI ≥ 30	<i>P</i> value	BMI < 30	BMI ≥ 30	<i>P</i> value
No of donors	903	205		201	201	
Gender (M/F)	392/511	79/126	0.20	76/125	77/124	0.92
Age (years)	55.0 (42.3–62.8)	50.5 (41.3–60.3)	0.03	52.8 (41.7–60.9)	50.7 (41.6–60.4)	0.58
ASA (1/2/3)	552/347/4	96/108/1	<0.001	91/109/1	96/104/1	0.88
Hypertension	115 (12.7)	43 (21.0)	0.004	37 (18.4)	40 (19.9)	0.70
Operative						
HARP/LDN	200/703	137/68	<0.001	134/67	133/68	0.92
Right/left kidney	288/615	51/154	0.046	53/148	50/151	0.73
Time (min)	152 (126–190)	161 (128–193)	0.17	152 (128–187)	161 (128–194)	0.22
Blood loss (mL)	50 (10–150)	168 (50–330)	<0.001	100 (50–200)	168 (50–330)	0.006
Postoperative						
Major complications (CDc ≥ 3)	7 (0.8)	3 (1.5)	0.38	1 (0.5)	3 (1.5)	0.30
LOS (days)	3 (2–4)	3 (3–4)	0.81	3 (3–4)	3 (3–4)	0.43
Kidney function						
Creatinine (mg/dL)						
Pre	75 (65–84)	73 (65.5–83)	0.21	74 (65.3–82)	73 (66–83)	0.98
1 month	111 (97–127)	111 (96–128)	0.60	111 (98–126)	111 (97–128)	0.80
3 month	110 (97–125)	109 (95–123)	0.51	111 (98–120)	109 (96–124)	0.89
1 year	108 (95–124)	106 (93–123)	0.94	108 (95–120)	107 (93–123)	0.63
Delta (1 year—pre)	33 (27–43)	34 (27–42.8)	0.39	34 (27–43)	34 (27–42.8)	0.66
eGFR (mL/min/1.73 m ²)						
Pre	84 (73–90)	85 (73.5–90)	0.45	83 (72–90)	85 (73.5–90)	0.48
1 month	52 (45–59)	52 (45–59)	0.87	51 (45–58)	52 (45–58)	0.45
3 month	53 (46–61)	53 (46–61)	0.72	51 (46–59)	53 (46–61)	0.37
1 year	54 (46–62)	54 (48–61)	0.75	53 (46–62)	54 (48–61)	0.76
Delta (1 year—pre)	–26 (–32 to –20)	–27 (–33 to –23)	0.21	–25 (–33 to –19)	–27 (–33 to –23)	0.17

Data were presented as means (standard deviation) or numbers (percentages)

BMI body mass index, *PSM* propensity score matching, *ASA* American Society of Anesthesiologists, *HARP* hand-assisted retroperitoneoscopic living donor nephrectomy, *LDN* laparoscopic living donor nephrectomy, *CDc* Clavien–Dindo classification, *LOS* length of stay, *eGFR* estimated glomerular filtration rate

similar postoperative outcomes compared to donors with BMI < 30. These results suggest that laparoscopic living donor nephrectomy for donors with BMI ≥ 30 is safe and feasible when looking at short-term outcome, without compromising outcomes. In addition, kidney function 1 year after donation did not differ significantly across the groups. This result supports a precious report that showed donor BMI was not associated with decline in eGFR and percent change in creatinine level at 6 month after kidney donation [6].

Regarding eligibility criteria for living kidney donor, the CARI guidelines considered obesity (BMI > 30) as a relative contraindication to donation [4]. The British guidelines recommended that individuals with BMI 30–35 should undergo careful preoperative evaluation, and individuals with BMI > 35 should be discouraged from donating because of limited data [16]. The consensus

statement of the Amsterdam Forum on the Care of the Live Kidney Donor also recommended that individuals with BMI > 35 should be discouraged from donating, especially when other comorbidities are present [17]. In contrast, The European Association of Urology and the Canadian guidelines have not provided any recommendations for donors with BMI > 30 [18–20]. Accordingly, the question concerning applicable cut-off values of BMI for obese donors remains under debate. A recent systematic review has concluded that the selection of potential kidney donors should not be based on BMI alone, and high BMI should not be considered as an absolute contraindication for living kidney donation. The transplant community should carefully screen each obese individual and make a selection for donation by an obese potential donor with a careful individualized process [21].

Another important issue would be the ethical aspect for long-term outcome after living donor nephrectomy in obese donors. Obese donors (BMI ≥ 30) have been reported to have an increased risk of diabetes mellitus, hypertension, and end-stage renal disease compared to non-obese donors (BMI < 30) during long-term follow-up after donation, although the absolute risk for these outcomes is relatively low [22, 23]. Furthermore, a recent study has reported that obese living kidney donors (BMI ≥ 30) had a 30% increased risk of long-term mortality compared with their non-obese donors (BMI < 30) [24]. Accordingly, we need to select potential obese donors, and pay attention to not only short-term outcome but also long-term outcome of living donor candidates.

Several limitations should be acknowledged in the present study. The present study is a retrospective, single-center analysis, and there may be a potential selection bias for living kidney donors. There were several rationales regarding the selection criteria for LDN or HARP although the final decision was made by the surgeon preference as described above. First female donors were prone to receive LDN because intraabdominal fat is generally less in female donors. Actually 69% of the LDN group were female compared to 58% of the HARP group although not statistically significant. Second we have gained more experiences of LDN in obese donors over the years. Third surgical comfort would be better in LDN compared to HARP. Another concern is long-term outcomes of obese donors. We examined the outcome at 1 year after donor nephrectomy; however, further long-term outcome after nephrectomy is not investigated in this study. The risk of lifestyle diseases and mortality is higher in obese donors (BMI ≥ 30) as we described above, therefore careful long-term follow-up for obese donors is needed, and is provided in our center. In addition, this study does not include recipients' outcome because we focus on only donor outcome based on the procedure (HARP vs. LDN) and donor BMI. However, a previous study has reported no significant differences in recipient acute rejection, allograft survival, and patient mortality across donor BMI categories [6]. Further prospective large studies are necessary to understand the long-term outcome of recipients from obese donors.

Conclusions

Our findings suggest that laparoscopic living donor nephrectomy for donors with BMI ≥ 30 is safe and feasible with good postoperative outcomes. There were no significant differences regarding postoperative outcome between HARP and LDN. Furthermore, the outcome in donors with BMI ≥ 35 was comparable to donors with BMI 30–35. BMI itself should not be considered as a contraindication in

selection criteria for living kidney donors, based on short-term outcome. However, additional long-term follow-up of donors is needed to examine the impact of donor obesity on outcome including chronic kidney disease and kidney function after living donor nephrectomy.

Funding The authors declare that they received no funding for this study.

Compliance with ethical standards

Disclosures K. Takagi, H. J. A. N. Kimenai, J. N. M. IJzermans, and R. C. Minnee have no conflicts of interest or financial ties to disclose.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Hamoir E, Defechereux T, Bonnet P, Honoré P, Meurisse M (2000) Laparoscopic living donor nephrectomy: university of Liège experience. *Transplant Proc* 32:486–487
2. Hazebroek EJ, Gommers D, Schreve MA, van Gelder T, Roodnat JI, Weimar W, Bonjer HJ, IJzermans JN (2002) Impact of intraoperative donor management on short-term renal function after laparoscopic donor nephrectomy. *Ann Surg* 236:127–132
3. Delmonico F, Council of the Transplantation Society (2005) A report of the Amsterdam forum on the care of the live kidney donor: data and medical guidelines. *Transplantation* 79:S53–S66
4. Isbel N, CARI guidelines (2010) The CARI guidelines. Donors at risk: obesity. *Nephrology (Carlton)* 15:S121–S132
5. Lafranca JA, Hagen SM, Dols LF, Arends LR, Weimar W, IJzermans JN, Dor FJ (2013) Systematic review and meta-analysis of the relation between body mass index and short-term donor outcome of laparoscopic donor nephrectomy. *Kidney Int* 83:931–939
6. Reese PP, Feldman HI, Asch DA, Thomasson A, Shults J, Bloom RD (2009) Short-term outcomes for obese live kidney donors and their recipients. *Transplantation* 88:662–671
7. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M (2009) The Clavien-Dindo classification of surgical complications: 5-year experience. *Ann Surg* 250:187–196
8. Williamson A, Hoggart B (2005) Pain: a review of three commonly used pain rating scales. *J Clin Nurs* 14:798–804
9. Kok NF, Alwayn IP, Lind MY, Tran KT, Weimar W, IJzermans JN (2006) Donor nephrectomy: mini-incision muscle-splitting open approach versus laparoscopy. *Transplantation* 81:881–887
10. Dols LF, Kok NF, Terkivatan T, Tran TC, d'Ancona FC, Langenhuijsen JF, zur Borg IR, Alwayn IP, Hendriks MP, Dooper IM, Weimar W, IJzermans JN (2010) Hand-assisted retroperitoneoscopic versus standard laparoscopic donor nephrectomy: HARP-trial. *BMC Surg*. <https://doi.org/10.1186/1471-2482-10-11>
11. Takagi K, Umeda Y, Yoshida R, Nobuoka D, Kuise T, Fushimi T, Fujiwara T, Yagi T (2019) The outcome of complex

- hepato-pancreato-biliary surgery for elderly patients: a propensity score matching analysis. *Dig Surg* 2019:323–330
12. Unger LW, Feka J, Sabler P, Rasoul-Rockenschaub S, Györi G, Hofmann M, Schwarz C, Soliman T, Böhmig G, Kainz A, Salat A, Berlakovich GA (2017) High BMI and male sex as risk factor for increased short-term renal impairment in living kidney donors—retrospective analysis of 289 consecutive cases. *Int J Surg* 46:172–177
 13. Schurman SJ, Stablein DM, Perlman SA, Warady BA (1999) Center volume effects in pediatric renal transplantation. A report of the North American Pediatric Renal Transplant Cooperative Study. *Pediatr Nephrol* 13:373–378
 14. Barbas AS, Dib MJ, Rege AS, Vikraman DS, Sudan DL, Knechtle SJ, Scarborough JE (2018) The volume-outcome relationship in deceased donor kidney transplantation and implications for regionalization. *Ann Surg* 267:1169–1172
 15. Burg JM, Scott DL, Roayaie K, Maynard E, Barry JM, Enestvedt CK (2018) Impact of center volume and the adoption of laparoscopic donor nephrectomy on outcomes in pediatric kidney transplantation. *Pediatr Transplant*. <https://doi.org/10.1111/ptr.13121>
 16. Andrews PA, Burnapp L, Manas D, Bradley JA, Dudley C, British Transplantation Society, Renal Association (2012) Summary of the British Transplantation Society/Renal Association U.K. guidelines for living donor kidney transplantation. *Transplantation* 93:666–673
 17. Ethics Committee of the Transplantation Society (2004) The consensus statement of the Amsterdam forum on the care of the live kidney donor. *Transplantation* 78:491–492
 18. Knoll G, Cockfield S, Blydt-Hansen T, Baran D, Kiberd B, Landsberg D, Rush D, Cole E, Kidney Transplant Working Group of the Canadian Society of Transplantation (2005) Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation. *CMAJ* 173:1181–1184
 19. Kälble T, Lucan M, Nicita G, Sells R, Burgos Revilla FJ, Wiesel M, European Association of Urology (2005) EAU guidelines on renal transplantation. *Eur Urol* 47:156–166
 20. Rodríguez Faba O, Boissier R, Budde K, Figueiredo A, Taylor CF, Hevia V, Lledó García E, Regele H, Zakri RH, Olsburgh J, Breda A (2018) European association of urology guidelines on renal transplantation: update 2018. *Eur Urol Focus* 4:208–215
 21. Ahmadi AR, Lafranca JA, Claessens LA, Imamdi RM, IJzermans JN, Betjes MG, Dor FJ (2015) Shifting paradigms in eligibility criteria for live kidney donation: a systematic review. *Kidney Int* 87:31–45
 22. Locke JE, Reed RD, Massie A, MacLennan PA, Sawinski D, Kumar V, Mehta S, Mannon RB, Gaston R, Lewis CE, Segev DL (2017) Obesity increases the risk of end-stage renal disease among living kidney donors. *Kidney Int* 91:699–703
 23. Serrano OK, Sengupta B, Bangdiwala A, Vock DM, Dunn TB, Finger EB, Pruett TL, Matas AJ, Kandaswamy R (2018) Implications of excess weight on kidney donation: long-term consequences of donor nephrectomy in obese donors. *Surgery* 164:1071–1076
 24. Locke JE, Reed RD, Massie AB, MacLennan PA, Sawinski D, Kumar V, Snyder JJ, Carter AJ, Shelton BA, Mustian MN, Lewis CE, Segev DL (2019) Obesity and long-term mortality risk among living kidney donors. *Surgery* 166:205–208

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.